AstraZeneca’s BioVentureHub and Mölnlycke collaborate to support knowledge exchange across the Swedish life science industry
AstraZeneca’s BioVentureHub announced today that it has established a new collaboration with Mölnlycke, a global medtech company headquartered in Gothenburg, Sweden.
From now on, small and medium-sized enterprises (SMEs) connected to AstraZeneca’s BioVentureHub will be offered free consultations with Mölnlycke experts with regard to developing products and solutions featuring medical device components.
The collaboration, which has no financial, legal or contractual obligations, aims to support knowledge exchange across the Swedish life science industry, strengthen innovation opportunities for future, integrated, drug-device therapies and stimulate growth of SMEs. The collaboration with Mölnlycke follows a similar collaboration between the BioVentureHub and IBM Sweden announced earlier this year.
'With increasing focus on precision medicine, patient centricity and preventative care, we need to think differently when we are designing healthcare solutions for the future. It’s not efficient nor sustainable to develop drugs, devices, diagnostics and digital health solutions in silos. As a life science industry, we need to build new structures for cross-sector collaboration and convergence . Our exciting collaboration with Mölnlycke further expands our unique collaboration environment, and offers SMEs and research groups invaluable access to Mölnlycke’s world-class medtech expertise and know-how,' says Magnus Björsne, CEO, AstraZeneca BioVenturehub.
'We already have an R&D lab located in the BioVentureHub, and we’ve seen first-hand the important role the BioVentureHub is playing to facilitate interactions and unlock knowledge exchange to fuel the growth of the Swedish life science ecosystem. By daring to share more of the learnings and capabilities we have acquired over the years, we are pleased and proud to have the opportunity to contribute to further strengthen the development of the life science industry and help SMEs on the path to transformative growth in healthcare,' says Barry McBride, Executive Vice President, R&D at Mölnlycke.
As part of the collaboration, the BioVentureHub and Mölnlycke, together with Devicia AB, will host a free webinar 'Successfully navigating MDR transition journeys' for SMEs on 23 September 2020.
Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. We design and supply products and solutions for use in wound treatment, pressure ulcer and infection prevention and surgery. Mölnlycke employs around 7,800 people. The company headquarters are in Gothenburg, Sweden and we operate in more than 100 countries worldwide. Since 2007, the company is part of Investor AB, an engaged owner of high-quality, global companies which was founded by the Wallenberg family in 1916. For more information, please visit www.molnlycke.com.
About AstraZeneca’s BioVentureHub
AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private-partnership model and located at the heart of AstraZeneca Gothenburg, the BioVentureHub gives emerging biotech & medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with−and tap into−the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other.
For more information please visit www.azbioventurehub.com